A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Epstein-Barr Virus DNA, Quantitative Real-Time PCR, Miscellaneous : 14163
Test CodeEBVMIS or 14163
Alias/See Also
EBV DNA, QN PCR * EBV * INFECTIOUS MONONUCLEOSIS * PTLD * LYMPHOPROLIFERATIVE * POST TRANSPLANT
CPT Codes
87799
Transport Container
1 mL (0.5 mL min) Whole Blood collected in an EDTA (lavender-top) tube.
1 mL (0.5 mL min) Serum collected in a Red-top tube (no gel) or Serum Separator Tube (SST®).
1 mL (0.5 mL min) CSF collected in a sterile plastic, leakproof container.
Alternative Specimen
1 mL (0.5 mL min) Bronchoalveolar Lavage collected in a sterile, plastic, leakproof container.
1 mL (0.5 mL min) Serum collected in a Red-top tube (no gel) or Serum Separator Tube (SST®).
1 mL (0.5 mL min) CSF collected in a sterile plastic, leakproof container.
Alternative Specimen
1 mL (0.5 mL min) Bronchoalveolar Lavage collected in a sterile, plastic, leakproof container.
Transport Temperature
Refrigerated
Specimen Stability
Room temperature: 48 hours; Refrigerated: 8 days; Frozen: 30 days except Whole blood (Unacceptable as Frozen)
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Frozen Whole Blood
Methodology
Real-Time Polymerase Chain Reaction
FDA Status
LDT with ASR reagent labeled by the manufacturer as Class I or Class II
Setup Schedule
Sunday - Saturday
Report Available
1 day
Limitations
Laboratory test results should always be considered in the context of clinical observations. This test was developed, and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
Reference Range
Not Detected
Clinical Significance
Monitoring EBV DNA levels by quantitative PCR in patients at risk of EBV-associated lymphoproliferative disorders may allow timely recognition of virus reactivation and permit installment of antiviral treatment. Reportable Range is 200-2,000,000 copies/mL (2.30-6.30 Log Copies/mL)
Performing Laboratory
med fusion